Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib- and acalabrutinib-treated patients

Blood. 2022 Jul 28;140(4):401-405. doi: 10.1182/blood.2021015132.

Gage S Black^{1

2}, Xiaomeng Huang^{1

2}, Yi Qiao^{1

2}, Szabolcs Tarapcsak^{1

2}, Kerry A Rogers³, Shrilekha Misra³, John C Byrd⁴, Gabor T Marth^{1

2}, Deborah M Stephens⁵, Jennifer A Woyach³

¹ Department of Human Genetics, University of Utah, Salt Lake City, UT;
² Utah Center for Genetic Discovery, School of Medicine, University of Utah, Salt Lake City, UT.
³ Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH.
⁴ Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH; and.
⁵ Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.

No abstract available

MeSH terms